Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Ovid Therapeutics (OVID) had Return on Tangible Equity of -8.57% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-16.99M |
|
-- |
|
-- |
|
$17.85M |
|
$-17.85M |
|
$0.86M |
|
$-16.99M |
|
$-16.99M |
|
$-16.99M |
|
$-16.99M |
|
$-16.99M |
|
$-16.99M |
|
$-17.85M |
|
$-17.81M |
|
136.17M |
|
136.17M |
|
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$160.15M |
|
$0.22M |
|
$65.48M |
|
$225.63M |
|
$15.75M |
|
$11.61M |
|
$11.61M |
|
$27.36M |
|
$198.27M |
|
$198.27M |
|
$198.27M |
|
167.27M |
|
| Cash Flow Statement Financials | |
$-13.90M |
|
$5.95M |
|
$88.98M |
|
$15.08M |
|
$96.00M |
|
$80.91M |
|
$1.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.17 |
|
-- |
|
-- |
|
0.06 |
|
0.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.90M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.57% |
|
|
Return on Tangible Equity |
-8.57% |
-7.53% |
|
-8.09% |
|
$1.19 |
|
$-0.10 |
|
$-0.10 |
|